How are pharmaceutical enterprises preparing for the day of submission?

[pharmaceutical network industry trends] August of this year is coming to an end For pharmaceutical companies, this is very stressful According to the relevant requirements of the Ministry of finance, the inspection materials for the quality inspection of accounting information in the pharmaceutical industry in 2019 will be submitted to the Ministry of finance before August 31 Before that, pharmaceutical companies were busy checking sales expenses, income and cost accounting Now there are only three days left for submission How are pharmaceutical enterprises preparing? According to the inspection content, the authenticity and legality of the cost, expense and income of the pharmaceutical enterprises are the key points of the inspection, including whether there is sufficient basis for the expenditure of sales expenses, whether it actually occurs, whether there is a rebate paid to the medical staff through expert consultation fee, research and development fee, publicity fee, etc Among them, from the perspective of legality, the inspection content from the compliance of pharmaceutical enterprises and extended inspection units with accounting laws and regulations, financial accounting system, internal control norms, to the compliance with national financial and tax laws and regulations and policies From the perspective of authenticity, the authenticity of costs and expenses is directly related to the pre tax deduction of corporate income tax, and the authenticity of income is directly related to the taxable income of corporate income tax According to the industry, the focus of the inspection can be understood as the inspection of the enterprise income tax situation In fact, from the recent trends of pharmaceutical enterprises, the news of resignation and shareholders' reduction continues For example, since July 2018, there have been 4 directors and senior managers of Jingfeng pharmaceutical leaving intensively, including Jian Weiguang, Ouyang Yanli, etc., the veteran of Yibai pharmaceutical At the same time, many shareholders, including executives, are reducing their holdings intensively In July this year, Hengrui pharmaceutical also released a notice on the progress of the reduction of shares held by the board of directors and supervisors As of July 18, 2019, the time limit for the implementation of the reduction plan has been more than half, with a cumulative reduction of 2.1143 million shares, totaling 138 million yuan It is reported that this is the third time in a year that Hengrui medicine has reduced its holdings According to the public 2018 annual report, in 2018, its R & D expenses reached 6.464 billion, a year-on-year increase of 25.58%, accounting for 37.11% of revenue At present, Hengrui medicine has five innovative drugs on the market, namely, arexib, apatinib, tiopefiglitazidine, pyrrolidine and carrizumab for injection However, there are various reasons for the reduction Experts believe that the reasons for the increase of the reduction plan of listed companies include cash flow, the need to achieve the turnover rate, and the impulsive reduction of large shareholders when the industry negative factors appear From the list of accounting information quality inspection in the pharmaceutical industry, 77 pharmaceutical enterprises were involved in the inspection Among them, the regulatory bureau of the Ministry of Finance inspected 15 pharmaceutical companies, including 5 listed pharmaceutical companies such as Hengrui pharmaceutical and 3 well-known international pharmaceutical companies such as Sanofi, and inspected 2 pharmaceutical companies respectively, a total of 62 enterprises, involving 22 listed companies or subsidiaries such as Zhifei biology and Tongrentang Now the day of sending newspapers is approaching The industry believes that this verification is undoubtedly a major blow to pharmaceutical enterprises, and directly hit the key points of pharmaceutical enterprises With the high cost of sales of pharmaceutical enterprises being rectified, the whole industry will face a deep reshuffle, and some pharmaceutical enterprises will even face a crisis of survival However, the industry also believes that the purpose of this inspection may be to open the way for medical insurance fee control, further achieve the goal of comprehensive treatment of the high drug price and solve the problem of expensive medical treatment for the people Moreover, in light of the news that the new round of centralized drug purchase will implement nationwide linkage, it is mainly to reduce drug prices.